Review of clinical practice guidelines relating to cognitive assessment in stroke

David McMahon, Clayton Micallef & Terence J. Quinn

To cite this article: David McMahon, Clayton Micallef & Terence J. Quinn (2022) Review of clinical practice guidelines relating to cognitive assessment in stroke, Disability and Rehabilitation, 44:24, 7632-7640, DOI: 10.1080/09638288.2021.1980122

To link to this article: https://doi.org/10.1080/09638288.2021.1980122

© 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

Published online: 20 Dec 2021.

Article views: 1434

Citing articles: 1 View citing articles

Full Terms & Conditions of access and use can be found at https://www.tandfonline.com/action/journalInformation?journalCode=idre20
Review of clinical practice guidelines relating to cognitive assessment in stroke

David McMahon, Clayton Micallef and Terence J. Quinn

Institute of Cardiovascular & Medical Sciences, University of Glasgow, Glasgow, UK; NHS Greater Glasgow & Clyde, Glasgow, UK

Abstract

Purpose: To assess the content, quality, and supporting evidence base of clinical practice guidelines (CPGs) with reference to cognitive assessment in stroke.

Materials and methods: We performed a systematic review to identify eligible CPGs pertaining to cognitive assessment in adult stroke survivors. We compared content and strength of recommendations. We used the AGREE-II (appraisal of guidelines for research and evaluation) tool to appraise the quality of the guideline.

Results: Eight eligible guidelines were identified and seven were rated as high quality (i.e., appropriately addressing at least four domains of the AGREE-II tool including "rigor of development"). There was heterogeneity in the recommendations offered and limited guidance on fundamental topics such as which cognitive test to use or when to perform testing. Generally, the lowest quality of evidence (expert opinion) was used to inform these recommendations.

Conclusions: Although assessment of cognition is a key aspect of stroke care, there is a lack of guidance for clinicians. The limited evidence base, in part, reflects the limited research in the area. A prescriptive approach to cognitive assessment may not be suitable, but more primary research may help inform practice.

Introduction

Stroke and cognitive decline are positively associated with advancing age [1,2]. They often co-exist with a bi-directional relationship. Stroke is associated with a spectrum of cognitive issues, often labelled using the umbrella term “vascular cognitive impairment”. Post-stroke cognitive impairments are highly prevalent with estimates suggesting important impairments in almost one in four stroke survivors [3].

Despite this, our understanding of best practice in managing stroke related cognitive deficits is limited and as a result there is considerable variation in practice [4]. Cognitive problems can manifest at all stages of the stroke journey, from pre-stroke cognitive impairment, through acute cognitive issues including delirium [5], to medium and longer term cognitive issues, including overt dementia [6,7].

The importance of post-stroke cognition to stroke survivors themselves is clear [8], particularly with regards to attention and visuospatial abilities.

In stroke research, priorities indicate improving the management of cognitive impairment is consistently voted the most important factor by stakeholders including stroke survivors and their care-givers, both in Scotland, and the UK [9,10]; however, this might not be universal given a Swedish study did not find is to be the number one priority [11].

The first step in managing stroke related cognitive problems is assessment and diagnosis. However, there is no consensus agreement on the optimal approach to cognitive assessment. Cognitive assessment can be defined as “[the] examination of higher cortical functions, particularly memory, attention, orientation, language, executive function (planning activities), and praxis (sequencing of activities)” [12–15]. The visuospatial domain of cognition may also be tested, and is highly relevant in stroke care [16]. This is particularly true with respect to visuospatial neglect.

To achieve this cognitive assessment, there are a wide variety of tools available [17,18], ranging from very short screening tools, through to longer multidomain assessments and then tools that attempt to give a diagnostic formulation. Some assessments focus on cognitive impairment through psychometric assessments, whereas others assess cognition through functional activities. There are further levels of variation as these cognitive
III. Describe the evidence base that informed the "systematically developed statements to assist practitioner decisions about appropriate health care for specific clinical circumstances" [23]. Important stroke-cognitive assessment themes where clinicians and policy makers may seek guidance include the timing of cognitive assessment, the approach to cognitive assessment, the training and expertise required and how to communicate and use results of these assessments.

Guidelines are not a panacea and the CPG label is not a guarantee of quality. Indeed, there has been recent concern about biases and other limitations in certain high-profile CPGs [24–26]. As with any collection of applied research data, there are methods for critical appraisal of CPG content. The development of the Appraisal of Guidelines for Research and Evaluation 2nd version (AGREE-II) provides a yardstick to judge CPG quality [26,27]. Various international bodies and professional societies produce guidelines and the recommendations included may differ across countries, healthcare systems, or professional groups. As methods for the collation, synthesis and critical appraisal of guideline content are now available, a potential useful application would be to use these methods in exploring the topic of cognitive assessment in stroke.

Aims

We set out to identify, compare, and appraise relevant CPGs pertaining to cognitive assessment in stroke survivors.

Specific objectives were to:

I. Compare content and recommendations of international CPGs.

II. Assess the quality of these CPGs using the AGREE-II tool.

III. Describe the evidence base that informed the recommendations.

Materials and methods

We followed best practice in systematic review and evidence synthesis. As there is no specific protocol or guidance for CPG synthesis, we used the Preferred Reporting Items in Systematic Review and Meta-Analysis (PRISMA) checklist where appropriate [28]. We registered our protocol at the Centre for Open Review and Meta-Analysis (PRISMA) checklist where appropriate [28]. We registered our protocol at the Centre for Open Science [29].

All aspects of the conduct of the review (title selection, data extraction, and quality assessment) involved two researchers (DM, CM) working independently and comparing results. Both are clinicians trained in systematic review but neither have any stake, or conflicts of interest with the CPGs reviewed. Consensus was reached through discussion with recourse to a third-rater (TQ) where needed.

Search strategy

We searched various, multidisciplinary electronic databases: Medline (OVID), Embase (OVID), and CINAHL (EBSCO) & PsycInfo (EBSCO) and both the Scottish Intercollegiate Guideline Network (SIGN) and National Institute of Clinical and Healthcare Excellence (NICE) websites from March 2008 to March 2021 (Figure 1).

We supplemented our literature search by liaising with international topic experts. We hand searched the websites of relevant specialist societies and guideline producers: American Heart Association (AHA), European Stroke Organisation (ESO), Stroke Foundation (Australia). We also contacted relevant professional associations: British Psychological Society, British Neuropsychological Society (BNS), Royal College of Occupational Therapists, Council of Occupational Therapists for European Countries, and the Stroke Psychology Special Interest Group of the World Federation for Neuro Rehabilitation (OPSYRIS – Organisation for Psychological Research in Stroke) (full search strategy and syntax can be found in Supplementary Materials).

Inclusion/exclusion criteria

We formulated our inclusion criteria using the "PICAR" approach recommended for guideline reviews (modified from the traditional PICO for clinical question framing and focussing on Population, Intervention, Comparator, Attributes, and Recommendations) [30].

We limited inclusion to English language guidance and publication within our search time window. Where more than one guideline was produced on the same topic by the same organisation, we selected the most recent publication. If a guideline was described as needing updated by the host organisation, but no update was available, and the guidance was still in the public domain then we included the CPG (Table 1).

Data extraction

Both reviewers extracted all relevant information from CPGs into a bespoke extraction form. We extracted general and topic specific guideline information: publisher of the guideline, country of origin, target population, method of evidence collation, method of evidence grading, method of evidence synthesis, evidence base for the recommendation(s) as well as the recommendations. We also pre-defined four specific areas of particular interest, namely around cognitive test to be used, timing of assessment, training required, and how to use the resulting data (Table 2). The extracted elements were compared to ensure both reviewers had consistent data. The master list of all verbatim extractions is in Supplementary Material as "Master table of all extracted recommendations & evidence strengths".

Quality assessment

We used the AGREE II tool to assess the quality of included guidelines [31]. AGREE-II consists of 23 items arranged into six domains: Scope and Purpose (three items), Stakeholder Involvement (three items), Rigour of Development (eight items), Clarity of Presentation (three items), Applicability (four items), and Editorial Independence (two items) [32–34] (Figure 2).

All guidelines with recommendations on cognitive assessment in stroke were assessed at the level of each AGREE-II domain item using a seven-point scale and transferring the results to a standardised form based on the AGREE template. The scoring system was ordinal with a score of 1 (strongly disagree) to 7 (strongly agree). A combined AGREE-II domain result was calculated using an aggregated score using (obtained score − minimum possible score)/(maximum possible score − minimum possible score)×100%. This was done as per the AGREE II user’s manual, and each domain had the same weighting [33].
Records identified through database searching (n = 4067) Additional records identified through other sources (n = 6)

Records after duplicates removed (n = 4073)

Records screened (n = 4073)

Full-text articles assessed for eligibility (n = 12)

Clinical guidelines AGREE scored (n = 8)

Clinical guidelines included in recommendation synthesis (n = 8)

Records excluded (n = 4065)

Full texts excluded (n=4) Not stroke (n=1) Not English (n=1) Research only (n=1) Not a CPG (n=1)

---

Figure 1. PRISMA flow diagram.

Table 1. PICAR inclusion criteria for the review.

<table>
<thead>
<tr>
<th>PICAR element</th>
<th>Study specific criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Population, clinical area, and characteristics</td>
<td>Adults (&gt;18 years old) with history of stroke, regardless of pre-existing cognitive status. Assessment could be performed in any clinical setting. Clinical practice guidelines will be categorised by setting and timing on the stroke pathway, defined as: Hyper-acute stroke (first 48 h) Acute stroke (first month) Rehabilitation Outpatient Community</td>
</tr>
<tr>
<td>Interventions</td>
<td>A global cognitive assessment strategy including screening tools and tools for assessment of delirium (but not including single domain specific tools designed for a specific purpose, i.e., aphasia tools).</td>
</tr>
<tr>
<td>Comparators</td>
<td>No direct comparators.</td>
</tr>
<tr>
<td>Attributes of CPGs</td>
<td>Language: English language or has English language version. Publication regions: Any. Version: Only the latest versions of CPGs are to be included. Age: From 2008 to 2021 inclusive ensuring only up to date practice is captured. Development strategies: Evidence-based medicine approach with synthesis of published literature and other information sources and explicit evaluation of the quality of the supporting data. Rating of evidence: Employs a systemic way of evaluating the given evidence for recommendations. Scope: CPGs assessing cognition in adult patients with stroke disease. Recommendations: Reports on ≥1 recommendations of interest.</td>
</tr>
<tr>
<td>Recommendation characteristics</td>
<td>Interventions: Recommendations must explicitly discuss ≥1 assessment of interest. Comparators: Recommendations do not require to compare against cognitive testing in other groups, i.e., non-stroke patients. Confidence level: Must describe how bias has been assessed and reduced where possible. Clinical considerations of interest How to assess: Which cognitive assessment to use. When to assess: Assessed by timing and setting. Who should assess: Which professionals should undertake these assessments and what training is required. How to use assessments: How should cognitive assessment inform care pathways and how should they be communicated to patients and families.</td>
</tr>
</tbody>
</table>
Table 2. Data extraction table of clinical practice guidelines.

<table>
<thead>
<tr>
<th>Characteristics of CPGs</th>
<th>RCP’16</th>
<th>SIGN 118</th>
<th>SIGN 119</th>
<th>NICE 162</th>
<th>IHF’10</th>
<th>ASF’17</th>
<th>CHS’19</th>
<th>AHA’16</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adults &gt;18 years old presenting with stroke</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Hyper-acute stroke (first 48 h)</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Acute stroke (first month)</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Rehabilitation of stroke</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Outpatient stroke</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Community stroke</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>A cognitive screening instrument</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>English language only in the first instance</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Where CPG published</td>
<td>UK</td>
<td>Scotland</td>
<td>Scotland</td>
<td>England and Wales</td>
<td>ROI</td>
<td>Australia</td>
<td>Canada</td>
<td>USA</td>
</tr>
<tr>
<td>Only the latest version of CPGs</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>2008–2019 inclusive</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Explicitly describes cognition or delirium testing</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Transparent method of evidence synthesis</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Systematic rating of the evidence</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Utilises only evidence-based medicine (EBM)</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Translating evidence is transparently appraised</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Assess all regardless of pre-existing cognitive status</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Comment on optimal assessment mode</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>Which professional is best placed to perform the assessment</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Timing of assessment</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>How to use the assessment data</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
</tbody>
</table>

Royal College of Physicians Stroke 2016 (RCP'16); SIGN stroke: June 2010 (SIGN 118); SIGN Dysphagia June 2010 (SIGN 119); NICE 162: Stroke June 2013 (NICE 162); Irish Heart Foundation 2010 (IHF'10); Australian Stroke Foundation 2017 (ASF'17); Canadian Heart & Stroke 2019 (CHS'19); American Heart & Stroke Association 2016 (AHA'16).

Figure 2. AGREE-II score of stroke clinical practice guidelines.

Judgements on each guideline’s overall quality were made by employing a standardised scoring rubric. Guidelines were of “high quality” if they adequately addressed at least four of the six AGREE II domains, including the “Rigour of Development” domain. To be considered as having adequately addressed a domain, a calculated AGREE-II result threshold of 50% or more had to be attained. If two or more domains were adequately addressed (or three domains except for “Rigour of Development”) CPGs were graded “moderate quality”. CPGs where only one, or no domains reached the 50% result were of “low” overall quality. There is no consensus on scoring AGREE-II data. As the topic CPGs could inform clinical practice, we prioritised the “Rigour of Development” domain, believing that all clinical guidance should be as evidence based as possible. For the same reasons, we set a high threshold for the label of “high” by mandating that at least four domains be adequately addressed. Our approach followed usual practice in other reviews of guidelines [35]. When interpreting AGREE-II, one should remember that the scoring relates to the quality and reporting of the published CPG rather than the evidence underlying the recommendations [32].

Recognising the potential for variation in AGREE-II assessments, it is recommended that all domains, as an aggregate, are compared using the intra-class correlation coefficient (ICC) [31,36], where values less than 0.5, between 0.51 and 0.75, between 0.76 and 0.9, and greater than 0.91 are indicative of poor, moderate, good, and excellent reliability, respectively [31]. Where disagreement remained following discussion (ICC score of less than 0.5), a third-rater (TQ) made a final judgement.

Data synthesis

We developed matrices of guideline recommendations to facilitate systematically comparing, categorising, and summarising the content across, and within CPGs (Table 3). Although the wording in each guideline differed, there were commonalities across the actions recommended. To allow an easily understood summary of the guideline content, we combined and condensed the recommendations. Full text of each recommendation was copied verbatim, creating a long list of free text statements. The list was assessed independently by DM and TQ, where recommendations
### Table 3. Stroke CPG recommendations and strength of evidence.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>How to assess cognition in stroke</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Use a validated tool for cognitive screening</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>In aphasia use a validated cognitive tool in conjunction with SLT</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Include assessment of ADL and IADL in cognitive assessment</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Who to assess for cognitive issues in stroke</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Assume all acute strokes have (or are at risk of) cognitive impairment</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cognitive screening should be routine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>When to assess for cognitive issues in stroke</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>If not improving, perform more detailed cognitive assessment</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>At point of discharge or transfer reassess cognition</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>If returning to cognitively demanding tasks perform detailed assessment</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>How to use results of cognitive assessments in stroke</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Use cognitive assessments to guide treatment</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Involve a (neuro)psychologist if severe/persisting problems</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>If cognitive issues identified, adjust information sharing accordingly</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>If cognitive impairment suspected screen for depression</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Provide educational materials around post stroke cognition</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>If persisting cognitive problems, consider compensatory or adaptive techniques</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### INTRACLASS CORRELATION

| | 0.78 | 0.67 | 0.83 | 0.76 | 0.57 | 0.74 | 0.88 | 0.95 |

**Key:**
- High quality guideline recommendation
- Moderate quality Guideline recommendation
suggested a common action, these were combined, and a summary text was created. This was an iterative process with comparison and discussion of the independent summaries. The process continued until no more recommendations could be combined. We present these summary descriptions in data matrices, where recommendations are cross-classified with guidelines and overall quality of evidence of the guideline. Full original text of each recommendation is available in Supplementary Materials.

The domain level quality of each guideline was collated and incorporated within a stacked polar chart. We had planned to covert the statements regarding the evidence supporting each recommendation into a standardised rubric to allow easy comparison however as all recommendations relied upon expert opinion only, we described this as a narrative.

**Results**

Our search yielded eight eligible CPGs (Figure 1), offering 27 recommendations regarding cognitive assessment in stroke. Of the 20 high profile guidelines selected for full text review following our initial scoping search, 12 did not have any mention of cognition and its assessment [37–48].

We were able to condense these into 14 common recommendations: three describing assessment; three describing assessment timing; two describing who to assess and six describing how the assessment should be used (Table 3). We also found four recent documents that were relevant to our question but did not completely meet our inclusion criteria: a guidance document from the Chinese Society of Geriatrics on Cerebrovascular Small Vessel Disease; a ESO White Paper on Cognitive Impairment in Cerebrovascular Disease; ESO-Karolinska Recommendations on Cognitive Assessment in Stroke Trials and Norwegian Directorate of Health Guidelines on Stroke (Supplementary Materials). We also note that an ESO guideline on Post Stroke Cognitive Impairment is in production and due for release in late 2021.

Seven CPGs were of high quality including the Royal College of Physicians (RCP), SIGN (two guidelines), Australian Stroke Foundation, Canadian Best Practice, AHA, and NICE. The Irish Heart Foundation CPG was judged moderate quality (Figure 2).

All included CPGs achieved greater than 50% in the Scope and Purpose domain. Seven CPGs achieved greater than 50% in Stakeholder Involvement and Rigour of Development. All CPGs achieved greater than 50% in Clarity of Presentation. Three CPGs achieved greater than 50% in Applicability. Seven CPGs achieved greater than 50% for Editorial Independence. Greatest variation was within the Stakeholder and Applicability domains.

The strength of evidence that underpinned all the recommendations was based on expert opinion and the wording of the recommendations was created by the guideline development groups. Where primary evidence was used to inform the CPGs, NICE guidance used indirect evidence from a Cochrane review [49] and Canadian guidance was partly based on test accuracy [50,51] and epidemiological studies [52].

**Discussion**

Despite the importance of cognitive impairment in stroke, in our review of English language guidelines, we found a limited number of CPGs offering recommendations with reference to cognitive assessment in stroke care settings. By comparison medical management and physiological monitoring during stroke featured in all the national guidelines assessed. The UK National Stroke Audit (Sentinel Stroke National Audit Programme (SSNAP)) [53] highlights the potential disparity between “psychological” and “medical” aspects of stroke care. Across the UK, availability of access to a clinical psychologist has the lowest audit compliance (12 of the 169 UK stroke centres included meet this criterion).

The included CPGs were generally of high quality when assessed using the AGREE-II tool, albeit there was variation across guidelines and across individual domains of the quality assessment. However, this high quality is not synonymous with clinically useful guidance. AGREE was developed with the intention of improving the comprehensiveness, completeness, and transparency of reporting in practice guidelines. The AGREE-II checklists are used to assess the process and content of CPGs. A guideline that concludes “more research is needed” could score well using AGREE-II but is not necessarily useful in practice.

Where guidance was offered in our eligible CPGs, there was consensus that post stroke cognitive impairment is common and should be assessed as part of routine clinical care. We pre-specified important clinical questions for planning stroke cognitive assessment. While the guidelines provided content on these themes, the recommendations were often generic rather than an explicit plan that could be implemented by clinicians. For example, only one CPG named a preferred assessment tool (Montreal Cognitive Assessment) while others recommend using a “validated” (an undefined concept) tool, some provide no elaboration and others give tables or appendices of various possible assessments. The vague nature of guidance offered was not unique to a country or guideline producing body, rather it was common to all the guidelines assessed.

Underpinning all the relevant recommendations was a lack of high-quality trial evidence and a reliance on expert consensus. This is not a criticism of the CPGs, as for the topic of post stroke cognitive assessment clinical trials are generally lacking. This situation is not unique to post stroke cognitive assessment. Other important aspects of stroke care such as management of aphasia often rely on expert consensus as definitive original research studies are limited, albeit the situation is improving with important new studies recently completed or ongoing [54]. In the context of rapidly evolving evidence base, CPGs need to promptly incorporate new data. We note that some guideline producers are moving to a “living” guideline approach, where the evidence is scanned regularly and recommendations updated as soon as required by new research.

Despite the critical importance of cognition in clinical practice, stroke guidelines are not alone in offering vague recommendations around cognitive assessment. Even in conditions with a cognitive focus, like dementia or delirium guideline bodies such as SIGN [55], NICE [56] and the RCP [57] are equivocal in their recommendations about the cognitive assessment to be used [55]. Here, a lack of primary research is less of an issue, as systematic reviews and meta-analyses of various cognitive screening tests are available [58,59].

The availability of a CPGs with clear and evidence-based recommendation is not a guarantee of implementation. There are well described clinician barriers to clinician engagement with guidelines. A full discussion of the barriers and facilitators is beyond the scope of this review, but important factors include, time, access, and ease of understanding the guidance and supporting evidence [60,61]. In this sense, more systematic reviews of CPGs, with summaries and critique of the CPG content, may help clinicians make sense of contentious areas of practice.

The CPG recommendations were all based on expert opinion – often considered the lowest form of evidence. Using randomised methods to inform practice in use of a test strategy is uncommon,
although research novel designs are emerging. While there are systematic reviews and meta-analyses of the properties of cognitive tests in stroke [62], the classical test accuracy paradigm of comparing a test to a gold standard is only partly helpful in clinical practice. More sophisticated methods involving comparative test accuracy, test-treatment-outcomes and user experience are needed if the next iterations of guidelines are to offer more concrete recommendations [63].

Perhaps it is not for a CPG to mandate a particular approach to cognitive assessment. The choice of approach to assessing cognition will vary based on the person to be assessed, the clinical question to be answered and the resources available. A degree of clinical judgement will always be needed, and CPGs are a source of guidance rather than standardised operating procedures. However, few would argue against the need for more primary research on cognitive assessment in stroke that can allow the clinician an evidence-based approach to their assessment.

Strengths and limitations

Our search strategy was robust with a professional librarian generating a comprehensive search strategy with iterative steps, ensuring as much relevant literature was captured as possible. We followed best practice in evidence synthesis, with all steps performed independently by at least two trained assessors. While neither of the assessors were experienced guideline producers, as consumers of guidelines in clinical practice both had a working understanding of what fellow clinicians need from CPGs. We used various approaches to data visualisation, taking data that exist across several axes, and creating easy to understand synthesis suitable for clinicians, researchers, and policy makers.

Some weakness of our work includes only capturing English language CPGs. Thus, our guidelines have an Australasia, North American, UK, and Ireland focus. We suspect guidelines from other countries, especially low- and middle-income countries may look quite different. We limited our review to only one aspect of the management of cognition in stroke, namely assessment. Our scoping of the literature suggests that a review of treatment options in post-stroke cognitive impairment may be equally limited by a lack of primary research. To aid data visualisation and summarising of the CPG text, we collated and condensed recommendations. In doing this, we tried to preserve the meaning and nuance of the original text, but it is possible some information could have been lost. Some CPGs included in our synthesis were described as out of date by the host organisations. In the absence of any new version of these materials, we still included these CPGs in our review.

Implications for practice, policy, and research

The motivation for this review was the perceived inconsistency in clinical approach to cognitive assessment in stroke. The review of guidelines does not suggest a preferred strategy. There are a multitude of cognitive assessment tools and it is unclear currently which one is best; this is an area that could benefit from greater standardisation [64]. The current lack of consensus among CPGs highlights the uncertainty in the clinician community. While it may not be possible or appropriate to give prescriptive guidance on the choice of cognitive assessment, recommendations on timing of assessment, training of assessors and modifications to assessment strategies for particular patient groups could inform clinical pathways and ultimately improve patient care. As well as standardising care, CPGs have an important role in bench marking best practice and clear guidelines around cognitive assessment may help improve the visibility and raise standards in cognitive assessment. A useful next step would be to ask the clinical stroke community what they want from CPGs around cognitive assessment.

Our use of the AGREE tool suggests that guidelines in the stroke cognition space are produced to a high quality. Although there is still scope to further ensure stakeholder involvement in production and greater consideration of the barriers and facilitators of implementation of the guidance – as these were the domains with the greatest variability across CPGs. In line with other quality assessment tools, there may be an argument for adding a further domain to AGREE to allow assessment of clinical relevance of the guidance. By developing a “clinical recommendation” quality assessment domain, it might be possible not only to drive up the reporting standards of clinical guidelines but to begin to comment on their inherent clinical utility of the guideline.

Conclusions

While stroke care has advanced hugely in recent decades, some elements are better considered and evidenced than others. Explicit guidance on hyperacute stroke therapy, underpinned by robust primary research has transformed stroke care. At present, the assessment of cognition in stroke is lacking useful guidance but this partly reflects the availability of original research in this area. Where recommendations are available, the guidelines tend to be of high quality but may lack clinical utility. Given the myriad of stroke cognitive presentations, clinician variation in management and differences in healthcare settings, prescriptive guidance on the exact approach to cognitive testing may not be suitable. Clinical guidelines are just that, guidance and are not a substitute for clinical judgement or consideration of patient preferences. However, further primary research on cognitive assessment would allow the next iterations of guidelines to offer a stronger evidence base that could hopefully improve the approach to assessment.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Funding

The author(s) reported there is no funding associated with the work featured in this article.

ORCID

Terence J. Quinn http://orcid.org/0000-0003-1401-0181

References


